243 related articles for article (PubMed ID: 27379402)
1. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
3. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types.
Lacy S; Yang B; Nielsen J; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1071-1082. PubMed ID: 29687244
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
Yang S; Lukey P; Beerahee M; Hoke F
Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
Bonate PL; Floret S; Bentzen C
Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic and pharmacodynamic analysis of bosutinib.
Hsyu PH; Mould DR; Abbas R; Amantea M
Drug Metab Pharmacokinet; 2014; 29(6):441-8. PubMed ID: 24919837
[TBL] [Abstract][Full Text] [Related]
9. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Houk BE; Bello CL; Kang D; Amantea M
Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
[TBL] [Abstract][Full Text] [Related]
10. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
12. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
Hu P; Chen J; Liu D; Zheng X; Zhao Q; Jiang J
Eur J Clin Pharmacol; 2015 Jul; 71(7):843-50. PubMed ID: 25995169
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
Goel V; Hurh E; Stein A; Nedelman J; Zhou J; Chiparus O; Huang PH; Gogov S; Sellami D
Cancer Chemother Pharmacol; 2016 Apr; 77(4):745-55. PubMed ID: 26898300
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Freiwald M; Schmid U; Fleury A; Wind S; Stopfer P; Staab A
Cancer Chemother Pharmacol; 2014 Apr; 73(4):759-70. PubMed ID: 24522402
[TBL] [Abstract][Full Text] [Related]
17. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.
Lin Y; Wang C; Gao W; Cui R; Liang J
Oncotarget; 2017 Jun; 8(26):42252-42261. PubMed ID: 28178685
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.
Liu X; Zhang Y; Chen Q; Zhan Y; Wang Q; Hu C; Yu C; Guo Z; Chen X; Zhong D
J Clin Pharmacol; 2018 Mar; 58(3):347-356. PubMed ID: 28967981
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
[TBL] [Abstract][Full Text] [Related]
20. Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.
Zhou X; Mould DR; Takubo T; Sheldon-Waniga E; Huebner D; Milton A; Venkatakrishnan K
Br J Clin Pharmacol; 2018 Jan; 84(1):35-51. PubMed ID: 28891222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]